Filter
Period
Filter by
recent search
Showing: 1 – 05 of 152 Regulated Information
New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
PARIS, France, 8 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference, 10-11 March 2022, in Barcelona, Spain. Presentations include data from…
Ipsen : 2023 CSM – Formalities for making available preparatory documents to the Meeting
INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023
Combined Shareholders’ Meeting of 31 May 2023
Please download the associated documents for more information.